Macrophage-derived TNF␣ is a critical mediator of inflammation and destruction in diseases such as rheumatoid arthritis and Crohn's disease. These studies were undertaken to develop an effective adenovirus-based strategy to specifically suppress TNF␣ in primary human macrophages. A variety of promoters and LTRs were evaluated for effective expression in the macrophage cell line RAW 264.7. The CMV promoter and the Visna LTR were the most strongly expressed and were therefore used to drive the expression of TNF␣ antisense fragments. In transient transfection assays, the antisense fragment terminating at the 3Ј end of the first exon (216 bp) was superior to the others (70 and 750 bp), when expressed under the control of either the
Introduction
Chronic inflammatory diseases, such as rheumatoid arthritis and Crohn's disease, are associated with the local expression of proinflammatory cytokines such as TNF␣, IL-1␤, IL-6 and IL-8. 1 Macrophage-derived TNF␣ has a prominent role since it is capable of regulating other cytokines such as IL-1␤, IL-6 and IL-8 and matrix metalloproteinases such as collagenase and stromelysin. 2, 3 Supporting the importance of TNF␣, biologic therapies that target TNF␣, employing receptors or monoclonal antibodies, are effective at ameliorating rheumatoid arthritis and Crohn's disease. 4, 5 However, current therapy provides only temporary relief and requires repeated administration. A gene therapy approach to specifically inhibit TNF␣ may provide more long-lasting benefit, avoiding the need for repeated administration.
The aim of this study was to develop an effective, potentially sustainable, mechanism to suppress TNF␣ employing an antisense approach. Although, many studies suggest that TNF␣ antisense molecules may be effective at inhibiting TNF␣ secretion, [6] [7] [8] [9] [10] controversy exists concerning the most effective TNF␣ antisense sequence. The 5Ј AUG transcription start site and sequences of the first exon flanking donor splice sites have recently been CMV promoter or the Visna LTR. Adenoviral vectors expressing the 216 bp TNF␣ antisense fragment, controlled by the CMV promoter or the Visna LTR, were both effective at suppressing LPS-induced TNF␣ secretion by primary human macrophages. However, the Visna LTR was more effective not only at suppressing LPS-induced TNF␣ secretion, but also IL-6, which is highly sensitive to TNF␣ secretion. These results demonstrate that effective, specific, suppression of TNF␣ in macrophages is possible, employing a directed antisense approach and a promoter system that is highly efficient in human macrophages. Gene Therapy (2001) 8, 223-231.
identified as two promising regions to target. 6, 7 While most studies have employed antisense sequences of 15 to 30 bp, 6 -10 longer sequences have not been examined. Another concern with the use of antisense oligonucleotides to suppress TNF␣, relates to the fact that effective suppression may require repeated administration for long-term effectiveness. The use of viral vectors to provide long-term local expression of antisense inhibitory molecules might circumvent this problem. The continued effectiveness of this approach will also depend on cell type-specific promoter regulation. 11 The use of cell-type or tissue-specific promoters, in combination with effective regulatory TNF␣ antisense molecules, would provide an important new approach for effective gene therapy. 12 Since macrophages are the principal source of TNF␣ in pathologic tissues, four categories of promoters were examined to determine if any might be more effective than the CMV promoter, which is commonly employed in adenoviral vectors. The CMV promoter and the Visna LTR were more active in the RAW 264.7 cells, a mature macrophage-like cell line, than the other categories of promoters examined. Therefore, they were employed to construct plasmids, which expressed different overlapping TNF␣ antisense sequences. A plasmid expressing human TNF␣ was cotransfected into murine RAW 264.7 cells together with plasmids expressing TNF␣ antisense fragments. The TNF␣ antisense fragments terminating at the 3Ј end of the first exon (216 bp) were more effective, when controlled by either the CMV promoter or the Visna LTR, compared with shorter (70 bp) or longer (750 bp) versions. Replication defective adenoviruses expressing the 216 bp TNF␣ antisense fragment, under the control of the CMV promoter and Visna LTR were constructed. Both vectors resulted in significant (P Ͻ 0.03 to P Ͻ 0.0001) suppression of the LPS-induced TNF␣ secretion by primary human macrophages. At limiting dilutions, inhibition of TNF␣ secretion was more effective when the antisense fragments were expressed by the Visna LTR, compared with the CMV promoter. Specificity was demonstrated by the observation that in culture supernatants from TNF␣ antisense-treated macrophages, IL-8 secretion was suppressed only when TNF␣ was greatly reduced. In contrast, IL-6 expression was highly sensitive to suppression of TNF␣, and the Visna LTR driven vector was more effective than that driven by the CMV promoter. These data suggest that the targeted suppression of TNF␣ production by human macrophages, employing an antisense approach, is feasible and highly effective.
Results
The CMV promoter and the Visna LTR are strongly expressed in RAW 264.7 macrophages In order to achieve the maximal inhibitory effect with TNF␣ antisense fragments in macrophages, a variety of promoters were examined to determine which ones were more strongly expressed. Four different categories of promoters were evaluated: (1) a viral promoter (CMV) and a retroviral LTR (Visna); (2) TNF␣-inducible promoters (stromelysin and collagenase promoters); (3) a promoter induced during macrophage differentiation (1.0 kb and 0.5 kb of the human lysozyme promoter); and (4) a promoter induced during macrophage activation (-615 and -120 bp of the TNF␣ promoter). Plasmids expressing the firefly luciferase reporter gene driven by each of these promoters or LTRs were employed by transient transfection in RAW 264.7 cells. Promoter activity peaked at 24 h, declining at 48 and 72 h (data not shown). At 24 h, the CMV promoter and the Visna LTR were more active constitutively than the other promoter systems examined ( Figure 1a) .
Additional experiments were performed to determine if the Visna LTR was preferentially expressed in macrophages, relative to the CMV promoter. Plasmids driven by the CMV promoter (pCMV␤gal) and the Visna LTR (pVisnaLuc) were cotransfected into RAW 264.7 cells or into murine embryonic fibroblasts. The ratio of the activity of the Visna LTR:CMV promoter in each cell type was determined. The Visna LTR, relative to the CMV promoter, was four-to five-fold more active in the murine macrophage cell line compared with the fibroblasts (Figure 1b) . Differences in promoter interactions or of protein or mRNA stability in the two cell types were not specifically examined in these experiments and could potentially account for the results observed. Nonetheless, these observations support the relative specificity of the Visna LTR in macrophages, consistent with the earlier in vivo studies, 13, 14 and they support the potential value of using the Visna LTR to direct regulatory molecules in macrophages. Therefore, in subsequent studies, both the Visna LTR and the CMV promoter were employed to regulate the expression of each of the TNF␣ antisense molecules (70 bp, 216 bp and 750 bp) (Figure 2a) . TNF␣ antisense vectors suppress human TNF␣ secretion in cotransfected RAW 264.7 cells Initial experiments were performed to document that each of the TNF␣ antisense molecules was expressed following transient transfection. Twenty-four hours following transfection, each of the TNF␣ antisense possessing plasmids, driven by the CMV promoter or the Visna LTR, was comparably expressed, relative to GAPDH, in RAW 264.7 cells, determined by RT-PCR (Figure 2b ). In order to determine the inhibitory effect and the effective concentration of the different TNF␣ antisense constructs, Gene Therapy plasmids expressing one of the TNF␣ antisense fragments (ASTNF216), regulated by either the CMV promoter or the Visna LTR, were cotransfected into RAW 264.7 cells with a plasmid expressing full length human TNF␣ (pCMVhTNF␣) (Figure 2c ). The human TNF␣ secreted into the medium 18 h following transfection was measured by an ELISA specific for human TNF␣. Murine TNF␣ did not interfere with the assay. In each experiment the 100% TNF␣ control was determined by cotransfection of the pCMVhTNF␣ with control vectors possessing either the CMV promoter or Visna LTR. In every experiment, these control vectors (pCMVLuc or pVisnaLuc) were employed at the same ratios as the antisense expressing vectors, and served as the 100% controls. The inhibition of human TNF␣ secretion increased as the concentration of the antisense vectors was increased from ratios of 1:1 to 1:3 ( Figure 2c ). Since no substantial increase of inhibition of TNF␣ secretion was observed at 1:4 or 1:5 ( Figure 2c ) and promoter interference was observed with the pCMVluc at the 1:4 and 1:5 ratios (data not shown), further studies were performed at the ratios of 1:1 and 1:3.
The 216 bp TNF␣ antisense fragment inhibits human TNF␣ secretion from transfected RAW 264.7 cells Experiments were performed to determine which TNF␣ antisense was superior, employing either the CMV promoter or the Visna LTR ( Figure 3 ). Since TNF␣ suppression was not substantially increased at the 1:4 and 1:5 ratios, and because promoter competition was observed at the higher ratios, subsequent experiments were performed keeping the concentration of the pCMVhTNF␣ constant, while the CMV promoter and Visna LTR driven control or TNF␣ antisense plasmids were transfected at ratios of 1:1 and 1:3. Employing the CMV promoter to drive the expression of the different TNF␣ antisense fragments, the 216 bp antisense was the most effective inhibitor of TNF␣ secretion (Figure 3a ). Although cotransfection with the CMV driven plasmids expressing the ASTNF70 and 750 fragments resulted in reduced (45-50%) TNF␣ secretion at the 1:1 ratio, only the pCMVASTNF216 significantly suppressed (56.5 ± 18.6%, P c Ͻ 0.03) TNF␣ secretion at this ratio (Figure 3a) . However, at the higher ratio (1:3), each antisense expressing plasmid resulted in significant suppression, which was greater with the ASTNF216 (85.8 ± 5.3%, P c Ͻ 0.00001), compared with ASTNF70 (64.6 ± 15.9%, P c Ͻ 0.02) or ASTNF750 (52.4 ± 14.8%, P c Ͻ 0.04). These observations suggest that, when regulated by the CMV promoter, the 216 bp antisense was the most effective.
The effectiveness of each antisense construct expressed under the control of the Visna LTR was also examined. Only the pVisnaASTNF216 resulted in significant suppression of TNF␣ secretion at 1:1 and 1:3 (51.5 ± 9.9% and 48.5 ± 14.5%, P c Ͻ 0.002 and Ͻ 0.03, respectively) ( Figure  3b ). In contrast to the results observed with the CMV driven plasmids, when controlled by the Visna LTR, neither the 70 bp nor the 750 bp TNF␣ antisense fragments, at either ratio, resulted in significant suppression of TNF␣ secretion. At the lower ratio (1:1), the Visna LTR and the CMV driven ASTNF216 vectors comparably suppressed TNF␣ secretion. However, at the 1:3 ratio, the vector expressing the 216 bp TNF␣ antisense molecules controlled by the CMV promoter was more effective (85.8%) than that driven by the Visna LTR (48.5%) (P = 0.05). No reduction of TNF␣ secretion was noted when either the control CMV or Visna plasmid ratio was increased from 1:1 to 1:3 (legend, Figure 3a and b), supporting the conclusion that promoter competition was not responsible for the results observed.
An additional control for specificity was performed. Cotransfection of either the 216 bp or the 750 bp TNF␣ antisense expressing plasmids at 1:3 ratios, together with the pCMVLuc, rather than the pCMVhTNF␣, did not result in suppression of the luciferase activity (Table 1) . Together, these observations document the effectiveness CMV TNFAS 216 (n = 5) 8 ± 33% CMV TNFAS 750 (n = 4) −17 ± 46% Visna TNFAS 216 (n = 4) −38 ± 21% Visna TNFAS 750 (n = 3) 21 ± 10%
LPS (10 g/ml) was added 72 h following infection and the culture supernatants harvested 18 h later, frozen, and used to measure TNF␣ by ELISA. After removing the supernatants, cell viability was determined by MTT assay, which was employed to normalize cytokine values. The TNF␣ induced from LPS-treated macrophages infected with AdGFP, represented 100% (1039 ± 217 pg/ml at 100 MOI and 1120 ± 308 pg/ml at 200 MOI). The values presented represent the mean ± 1 s.e. of six independent experiments, each performed in triplicate. The TNF␣ is presented as a percentage of the AdGFP-infected macrophages (control). The * indicates P Ͻ 0.03 and ** P Ͻ 0.0001 compared with the control. (b and c). Following AdVisna-and AdCMV-ASTNF216 infection, LPS-induced IL-8 and IL-6 secretion correlate with TNF␣ secretion. M-CSF differentiated macrophages were infected, and the supernatants harvested as described in panel a. The culture supernatants were employed to measure TNF␣, IL-8 and IL-6 by ELISA. AdGFP infected, LPS-treated macrophages served as the 100% control. The values were normalized for cell viability and the relationship between the concentration of TNF␣ and IL-8 (panel b) or TNF␣ and IL-6 (panel c) examined by regression analysis.
The indicated antisense plasmids (2.25 g) were cotransfected with pCMVLuc (0.75 g), and lysates harvested after 24 h to measure luciferase activity, as described in Materials and methods. −, indicates that the mean value increased.
ies examined the effect of increasing concentrations of AdCMV-ASTNF216 and AdVisna-ASTNF216 on LPSinduced TNF␣ secretion by human macrophages ( Figure  4b ). At 50, and to a lesser degree 100 MOI, TNF␣ secretion was reduced to a greater degree by the Visna LTR regulated vector. However at 200 MOI, TNF␣ secretion was reduced comparably. Further studies were performed at 100 and 200 MOI to define the extent of the suppression of LPS-induced TNF␣ by each vector (Figure 5a ). At 100 MOI both the CMV promoter and the Visna LTR driven antisense vectors resulted in significant suppression of TNF␣ secretion (49.4 ± 15.5, P Ͻ 0.03; and 77.2 ± 6.3, P Ͻ 0.0001, respectively). At this concentration of virus (100 MOI), the Visna LTR driven antisense resulted in significantly greater suppression (P Ͻ 0.05) compared with the CMV promoter. In contrast, at the higher concentration (200 MOI), no difference was observed between the vectors and each significantly suppressed LPS-induced TNF␣ secretion (64.9 ± 13.2%, P Ͻ 0.005; and 81.0 ± 5.1%, P Ͻ 0.00002). The Visna LTR driven vector provided more consistent results, determined by the smaller standard deviations, at each concentration of virus. These observations indicate that, at the lower concentration, the Visna LTR was superior to the CMV promoter, at delivering TNF␣ antisense fragments that suppressed TNF␣ secretion.
Effect of inhibition of TNF␣ by antisense vectors on IL-8 and IL-6
The effect of inhibition of TNF␣ by the antisense expressing vectors on IL-8 secretion was determined. Compared with infection with the control AdGFP, LPS-induced IL-8 secretion was not significantly reduced following infection with AdCMV-ASTNF216 (5.0% and 12.0% suppression at 100 and 200 MOI, respectively) ( Table 2 ). In contrast, macrophage infection with the AdVisna-ASTNF216 resulted in modest suppression of the LPSinduced secretion of IL-8, which was reduced by 27.5 ± 8.4% at 100 MOI (P Ͻ 0.03), and by 37.4 ± 10.6%, at 200 MOI (P Ͻ 0.02). When the data from every experiment, at both concentrations of virus were pooled, there was a significant correlation between the concentrations of TNF␣ and IL-8 (r = 0.63, P Ͻ 0.001) (Figure 5b ). These observations indicate that the effects of the vector was not non-specific and suggest that the modest reduction of IL-8 observed with the AdVisna-ASTNF216 infected cells was due to the greater reduction of TNF␣.
Since TNF␣ may affect the expression of other cytokine genes differently, and since IL-6 secretion in rheumatoid arthritis was exquisitely sensitive to inhibition of TNF␣, the effect of the TNF␣ antisense-mediated inhibition of TNF␣ on IL-6 secretion by LPS-stimulated macrophages was also examined. The reduction of IL-6 was greater than observed for IL-8 ( Table 2 ). The Visna LTR driven TNF␣ antisense suppressed IL-6 more effectively than that controlled by the CMV promoter 100 and 200 MOI (P Ͻ 0.02 and Ͻ 0.05, respectively) ( Table 2 ). The correlation between the secretion of TNF␣ and IL-6 was highly significant (r = 0.87, P Ͻ 0.001) (Figure 5c ). In contrast to the suppression of IL-8, which was never complete, even when TNF␣ was not detected in the supernatants, the secretion of IL-6 was tightly associated with TNF␣ secretion. These observations suggest that in contrast to IL-8, the secretion of IL-6 by macrophages following LPS stimulation was highly dependent upon TNF␣ expression.
Discussion
Two novel observations are forthcoming from these data. First, employing an antisense approach, utilizing replication defective adenoviral vectors, inhibition of LPSinduced TNF␣ secretion by macrophages is feasible and effective. Second, in primary in vitro differentiated macrophages, despite the fact that the CMV promoter was substantially more active following transient transfection in a macrophage cell line, the Visna LTR was more effective at suppressing TNF␣ secretion, and subsequently IL-6 secretion, employing a TNF␣ antisense approach. This study was unique since it examined the use of large fragments of antisense delivered by plasmids and replication defective adenoviral vectors. This approach allowed the antisense molecules to be delivered as a renewable source under the control of the CMV promoter or the Visna LTR, rather than a single bolus, as employed in previous studies. [6] [7] [8] [9] [10] This study demonstrated by transient transfection that the 216 bp TNF␣ antisense was more effective than shorter (70 bp) or longer (750 bp) versions. Each of the antisense fragments constructed included the AUG transcription start site. Targeting the AUG start site, employing short oligodeoxynucleotides, was previously shown to be effective in suppressing TNF␣ secretion. 10 However, our 70 bp and 750 bp vectors also possessed the AUG start site and were not as effective as the 216 bp fragment, suggesting that the 5Ј AUG start site was not solely responsible for the effectiveness of the 216 bp antisense.
The effectiveness of the 216 bp TNF␣ antisense may also relate to the fact that it terminated precisely at the 3Ј end of the first exon of the TNF␣ gene. The shorter 70 bp fragment was not as effective, supporting this interpretation. Consistent with this observation, TNF␣ oligodeoxynucleotides targeted to exon sequences flanking the first donor splice site were more effective than other sequences. 7 This design may be responsible for the effectiveness of the 216 bp sequence, allowing it to interact more efficiently. However, the 750 bp TNF␣ antisense, which included all the elements of the 216 fragment, was less effective. It is possible that steric inhibition prevented the larger fragments (750 bp) from interacting as effectively as the shorter 216 bp version. Our observations document the importance of targeting specific sequences in the development of effective TNF␣ antisense mol- Table 2 ecules. Further studies will be required to determine if the effectiveness of termination of antisense molecules at the first exon/intron splice site is a general phenomenon, or is restricted to TNF␣.
Prior studies documented enhanced Visna LTR transgene expression in the activated macrophages of transgenic mice. 13 Consistent with this observation, the Visna LTR was relatively more active than the CMV promoter in RAW 264.7 macrophages compared with fibroblasts. However, the human lysozyme promoter, which was also effective at driving the expression of regulatory molecules in macrophages in transgenic mice, was not effective, at 0.5 or 1.0 kb, following transient transfection in RAW 264.7 cells. It is possible that the lysozyme promoter, or one of the other promoters, may also be effective in more differentiated or activated macrophages. However, the fact that their expression was so much less by transient transfection, precluded further development in adenoviral vectors. These observations indicate that the effects of promoter expression in transgenic animals can not be related directly to the development of celltype or tissue-specific promoters for vectors designed for gene therapy.
The Visna LTR was more effective at suppressing TNF␣ at lower concentrations of the viruses. Infection with the AdGFP indicated that most macrophages were infected at 100 MOI and the effect of more virus was an increased intensity of GFP expression. At the higher concentrations of virus employed (200 MOI), the ASTNF216 expressed by the CMV promoter were as effective as those expressed by the Visna LTR, for the suppression of TNF␣ secretion. A downstream effect of the inhibition of TNF␣ secretion was the suppression of IL-8 and IL-6. The explanation for the differences in the effectiveness of the Visna LTR and the CMV promoter, for the suppression of IL-8 and IL-6 is not clear. Since the concentrations of both IL-8 and IL-6 were highly correlated with the concentration of TNF␣, it is likely that the greater reduction of TNF␣ in the supernatants of cells infected with the AdVisna-ASTNF216, compared with those infected with AdCMV-TNFAS216, had a relevant effect on the expression of the cytokines (IL-8 and IL-6) downstream of TNF␣. The ASTNF216 driven by either the Visna LTR or the CMV promoter was comparably detected by RT-PCR (data not shown). However, no effort was made to quantitate the message by quantitative RT-PCR or an RNase protection assay. Nonetheless, it is possible that differences in the expression or stability of the antisense messages regulated by the CMV promoter or the Visna Gene Therapy LTR may have accounted for the differences observed. Further studies will be needed to determine if relevant differences will be observed in macrophages in vivo, when adenoviral vectors are employed to deliver effector molecules.
TNF␣ has been shown to play a regulatory role for IL-8 and IL-6 in human monocytes and macrophages. 2, 15 The partial suppression of IL-8 secretion, even with essentially complete inhibition of TNF␣ secretion, is consistent with results observed with LPS-stimulated human blood monocytes. 15 The exquisite sensitivity of IL-6 secretion to the inhibition TNF␣ was somewhat surprising. However, in recent clinical trials of patients with rheumatoid arthritis treated with anti-TNF␣ monoclonal antibody, IL-6 was completely normalized within 24 h of treatment, suggesting the direct regulation of IL-6 secretion by TNF␣. 16 Our data suggest that even following LPS stimulation, IL-6 secretion by differentiated macrophages was highly dependent upon TNF␣ secretion. The fact that the TNF␣ antisense was capable of suppressing IL-8 and IL-6 secretion, documents that they are, even following LPS stimulation, downstream of TNF␣ secretion in activated macrophages. This observation supports the potential value of this approach in the therapy of patients with rheumatoid arthritis or Crohn's disease.
In summary, these observations suggest that the antisense approach to suppression of TNF␣ is effective, not only at suppressing TNF␣ itself, but also cytokine genes regulated downstream such as IL-6, and to a lesser degree, IL-8. The design of the TNF␣ antisense and the promoter were important in obtaining an effective system. Further studies will be needed to determine if this approach will be effective in the long-term suppression of TNF␣ in vivo.
Materials and methods

Transient transfection
Murine RAW 264.7 macrophages were seeded into sixwell plates (Costar, Corning, NY, USA) at a density of 0.5 × 10 6 cells/well, in 3 ml of Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat inactivated fetal bovine serum (FBS), containing l-glutamine (1 mm), penicillin (100 units/ml) and streptomycin (100 g/ml). Cells were incubated for 18-24 h at 37°C in a CO 2 incubator. When 50-80% confluent, they were transfected employing Lipofectamine (Life Technologies, Gaithersburg, MD, USA) as previously described, 17, 18 keep-ing the total plasmid concentration constant. The supernatants and cells were harvested after 18 h. Cell extracts were obtained by freeze-thawing and luciferase activity and total protein were determined for each extract as previously described. [17] [18] [19] The supernatants were frozen until further use.
Plasmid vectors: antisense TNF␣ plasmids
The antisense constructs were generated by PCR employing a plasmid (pE4 from ATCC, Bethesda, MD, USA) that contains the entire coding as well as the 5Ј untranslated region of the human TNF␣ gene. The primers were designed to obtain three antisense fragments. Each fragment possessed 31 base pairs (bp) of the 5Ј untranslated region and variable lengths of the translated portion of the TNF␣ gene. These antisense molecules possessed a total of 70, 216 and 750 bp and were designated as ASTNF70, ASTNF216 and ASTNF750 respectively ( Figure 2 ). The primers used contained HindIII and XhoI sites at their 5Ј and 3Ј ends, respectively. Each of these antisense fragments was cloned downstream of either the CMV promoter or the Visna LTR, in a construction vector possessing the adenoviral 5Ј ITR and packaging sequence, and were designated pCMVASTNF70 and pVisnaASTNF70, etc. The resulting plasmids were verified by restriction digest and sequencing to ensure the presence of the expected antisense fragments.
Promoter reporter constructs
The pCMVLuc has been previously described. 20 The LTR of the visna virus, a member of the lentivirus family, was derived from the pVisnaLTRCAT, obtained from Dr Janice Clements, Johns Hopkins University, 13 and digested with XhoI and HindIII to release a 750-bp fragment containing the LTR, which was cloned into pGL basic vector (Promega, Madison, WI, USA) upstream of the luciferase gene (pVisnaLuc). The pHIVLuc was kindly provided by Dr M Furtado, Northwestern University Medical School. The pcollLuc was previously described. 20 Two versions (0.5 kb and 1.0 kb) of the human lysozyme promoter were prepared employing the plasmid BH7.4 which possessed 2255 bp of the human lysozyme promoter 21 (a gift of Dr David R Greaves, University of Oxford, UK). DNA sequences containing 1004 and 541 bp (−22 to −1026 and −22 to −563 bp, respectively), were PCR amplified and cloned between KpnI and HindIII sites of the pGL2 basic vector (Promega) to give rise to pLys-0.5Luc and pLys-1.0Luc, respectively. The Stromelysin promoter-reporter plasmid (pStromLuc) consists of 480 bp of human stromelysin promoter sequences (−450 to +30), fused to the luciferase reporter gene in the pGL2 basic vector (Anderson and Thimmapaya, unpublished). Plasmids containing two different fragments of the human TNF␣ promoter (−615 bp and −120 bp) were previously described. 22 A plasmid expressing placental alkaline phosphatase regulated by the SV40 promoter (pSV40AP) and one expressing ␤-galactosidase driven by the CMV promoter (pCMV␤gal) were also employed. Luciferase activity was performed as previously described 17, 18, 23 and the alkaline phosphatase and ␤-galactosidase activities were performed according to the manufacturer's recommendations (Tropix, Inc., Bedford, MA, USA; and Clonetech Laboratories, Inc., Palo Alto, CA, USA).
Adenovirus construction
To generate replication-defective adenoviruses expressing the ASTNF216 fragment, driven by the CMV promoter or the Visna LTR, each plasmid (pCMVASTNF216 and pVisnaASTNF216) was digested with the appropriate enzymes (HindIII and XhoI). The fragments possessing the adenoviral 5Ј ITR and packaging sequence, the CMV promoter or the Visna LTR, the TNF␣ antisense sequences and the SV40 poly A sequences were ligated to map units 4 to 100 of Ad309/356 DNA, as previously described. 24, 25 The ligation mixture was transfected into 293 cells. The resulting viruses were plaque purified and the appropriate inserts confirmed by restriction digestion and by sequencing, as previously described. 23 The virus particles were purified by cesium chloride gradient centrifugation. 18, 23 The adenoviral titers (plaque forming units (p.f.u.)/ml) were determined by standard viral plaque assays using 293 cells. 18, 24, 25 Our virus preparations showed about 200 particles/p.f.u. and we did not see any significant differences in these ratios between the different batches of adenovirus employed in this study.
Reagents LPS, Histopaque, and antibiotics were purchased from Sigma Chemical Co (St Louis, MO, USA). Culture media (DMEM, RPMI, and Opti-MEM), fetal calf serum (FCS) and fetal bovine serum (FBS) were obtained from Gibco (Gaithersburg, MD, USA). RNAzol B reagent for RNA isolation was from Tel-Test Inc. (Friendswood, TX, USA). The M-CSF was kindly provided by Genetics Institute (Cambridge, MA, USA).
Isolation, differentiation and infection of monocytes/macrophages
Mononuclear cells were isolated from buffy coats obtained from normal human peripheral blood, by Histopaque gradient centrifugation. Monocytes were separated from mononuclear cells by elutriation, using an Avanti TM J25I centrifuge (Beckman, Fullerton, CA, USA). Monocytes were у90% pure as determined by morphology, by non-specific esterase staining and by CD68 positivity employing immunohistochemistry or flow cytometry. Monocytes were further purified by adherence to plastic in RPMI (0.5 × 10 6 cells per well in 24-well plates (Costar, Corning, NY, USA)), without serum, for 1 h. After washing three times, RPMI medium containing l-glutamine (1 mm), penicillin (100 units/ml), streptomycin (100 g/ml), M-CSF (100 ng/ml) and 10% of heat-inactivated FCS, was added to the wells for 7 days. 18, 23 Following differentiation, the medium was aspirated and the cells were exposed to virus at 50, 100 or 200 MOI per cell, in 200 l of serum-free RPMI. After 2 h, 200 l of RPMI containing 10% heat-inactivated FCS was added and the cells were incubated overnight at 37°C. The cells were then rinsed with PBS and 1 ml/well of RPMI containing 10% of FCS was added. After 72 h of infection, TNF␣ secretion was induced by treatment with LPS at 10 g/ml for 18 h. Macrophage viability at the end of each experiment was determined by MTT assay. 26 ELISA assay TNF␣, IL-6 and IL-8 were measured by ELISA, employing commercially obtained reagents (R&D Systems, Minneapolis, MN, USA), as previously described.
RT-PCR
Total cellular RNA was extracted from cells and employed to generate cDNA using the Reverse Transcription System (Promega). The cDNA was amplified using specific G3PDH (Clonetech) or TNF␣ antisense/SV40 polyA sequence primer pairs respectively for 30 cycles. Each cycle consisted of denaturation at 94°C for 30 s, annealing at 50°C for 45 s, and extension at 72°C for 90 s. PCR products were analyzed by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining. For amplifying the antisense mRNA the 3Ј primer for SV40 was: TCTTCCAGCTGGAGAA-GGGTGACCGACTCAG and the 5Ј primer TNF␣ antisense primer was: AACCTCTACAAATGTGGTATGGT.
Statistical analysis
Differences between the amount of TNF␣ secreted were analyzed by Student's t test or t test for matched pairs. Values are expressed as mean ± 1 standard error of mean (s.e.). When multiple, potentially related comparisons were made, the observed P values were corrected (P c ) for the number of observations.
